Serigen Mediproducts Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 18-12-2024
- Paid Up Capital ₹ 0.17 M
as on 18-12-2024
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 126.46%
(FY 2022)
- Profit -7.08%
(FY 2022)
- Ebitda -9.94%
(FY 2022)
- Net Worth -36.25%
(FY 2022)
- Total Assets -28.83%
(FY 2022)
About Serigen Mediproducts
The Corporate was formerly known as Biolmed Innovations Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.17 M, as per Ministry of Corporate Affairs (MCA) records.
Uday Chatterjee, Premnath Venugopalan, Priti Rao, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74900PN2015PTC153912
- Company No.
153912
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2015
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Serigen Mediproducts?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uday Chatterjee  | Nominee Director | 21-Jul-2023 | Current |
| Premnath Venugopalan | Director | 03-Feb-2015 | Current |
| Priti Rathi | Nominee Director | 03-Jun-2015 | Current |
| Priti Rao | Director | 15-Jan-2020 | Current |
| Anuya Nisal | Director | 03-Feb-2015 | Current |
Financial Performance and Corporate Structure Insights of Serigen Mediproducts.
Serigen Mediproducts Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 126.46% increase. The company also saw a slight decrease in profitability, with a 7.08% decrease in profit. The company's net worth observed a substantial decline by a decrease of 36.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Serigen Mediproducts?
In 2022, Serigen Mediproducts had a public holding of 33.41%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Entrepreneurship Development CenterActive 17 years 11 monthsPremnath Venugopalan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Serigen Mediproducts?
Unlock and access historical data on people associated with Serigen Mediproducts, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Serigen Mediproducts, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Serigen Mediproducts's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
